Tanshinone IIA potentiates the efficacy of 5-FU in Colo205 colon cancer cells in vivo through downregulation of P-gp and LC3-II

Introduction

Colorectal cancer is the third leading cause of cancer-related mortality in Taiwan (1) and the second leading cause of cancer-related mortality in Western countries (2,3). Traditional Chinese herbal medicines are widely accepted as an option for the treatment of colorectal cancers and there are intense efforts under way to identify new herbs and bioactive pure compounds (4,5). Danshen (Salviae miltiorrhizae Radix) is widely prescribed in traditional Chinese medicine for cardiovascular diseases (6,7). Tanshinone IIA (Tan-IIA; C19H18O3) is extracted from Danshen (8,9), and possesses anti-inflammatory (10,11) and antioxidant properties (12,13). Our previous studies have shown that Tan-IIA inhibits growth and induces apoptosis in Colo205 human colon cancer cells (14) and MDA-MB-231 breast cancer cells in vitro (15). 5-Fluorouracil (5-FU) is one of the chemotherapeutic medicines for colon cancer, but has low efficacy (16). To increase its therapeutic potential, there is interest in combining it with another medicine. The efficacy of Tan-IIA plus 5-FU in human colon cancer cells has not been established. Accordingly, we investigated the effects of Tan-IIA and 5-FU in a Colo205 human colon cancer cell xenograft model.

Materials and methods

Materials

Tan-IIA (purity >96%; HPLC) was purchased from Herbasin Co. (China). Aprotinin, antipain, sodiumdeoxycholate, leupeptin, sodium orthovanadate, Triton X-100 and Tris-HCl were obtained from Sigma-Aldrich (St. Louis, MO, USA). Dimethyl sulfoxide (DMSO), potassium phosphate and TE buffer were purchased from Merck KGaA (Darmstadt, Germany). RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Gibco BRL (Grand Island, NY, USA). Antibodies to P53, P21, VEGF, MMP-2 and -7, Topoisomerase I, Erb-B2, P-glycoprotein (P-gp), LC-3II, Bcl-2 and β-actin were obtained from Sigma-Aldrich. Penicillin-streptomycin, Trypsin-EDTA and glutamine were obtained from Gibco BRL. Sodium dodecylsulfate polyacrylamide gel and electrophoresis (SDS-PAGE) running buffer (10X), Tris, Tween-20, SDS and 5X TBE buffer were obtained from Amresco (St. Louis, MO, USA). BioMax film was obtained from Kodak.

Cell cultures

The Colo205 human colon cancer cell line was obtained from the Food Industry Research and Development Institute (Hsin-chu, Taiwan). The cells were placed into tissue culture flasks (75 cm2, 250 ml) and grown at 37°C in humidified 5% CO2 and 95% air atmosphere in RPMI-1640 medium containing 10% heat-inactivated FBS, 1% HEPES, 1% sodium pyruvate, 1% glutamine and 2% penicillin-streptomycin (10,000 U/ml penicillin; 10 mg/ml streptomycin).

In vivo tumor xenograft study

In the present study, 5-week-old male nude SCID mice (24 in total) were xenografted with Colo205 colon cancer cells (3×106/0.2 ml) and maintained in a pathogen-free environment (Laboratory Animal Center of Tzu Chi University, Hualien, Taiwan). From day 10, SCID mice bearing Colo205 human colon cancer cell engrafts were divided randomly into 3 groups and then treated with 5-FU (20 mg/kg, every week on day 1) plus Tan-IIA (20 mg/kg, every week on days 3 and 5), 5-FU (20 mg/kg, every week on day 1) plus corn oil (every week on days 3 and 5) or the vehicle alone (normal saline, every week on day 1 and corn oil every week on days 3 and 5) (Fig. 1). Following xenograft transplantation, mice exhibiting tumors were monitored and tumor size was measured once every 3 days using calipers. The tumor volume in each animal was estimated according to the formula: tumor volume (mm3) = L × W2/2 (where L is the length and W is the width) with the final measurement taken 4 weeks after tumor cell inoculation. At the end of the 4-week dosing schedule, the SCID mice were sacrificed with CO2 inhalation, xenograft tumors were dissected and total protein extracted for western blot analysis. The animal use protocol has been reviewed and approved by the Institutional Animal Care and Use Comittee (IACUC) Board, TZU-CHI Hospital (IACUC Approval No: 97-21).

Figure 1. Colo205 human colon cancer cell xenograft tumors were treated with 5-FU or 5-FU plus Tan-IIA for 4 weeks. Controls were separately treated with normal saline and corn oil. 5-FU, 5-fluorouracil; Tan-IIA, tanshinone IIA; QW1, every week on day 1; QW3,5, every week on days 3 and 5; I.P., intraperitoneally.

Synergistic effects of Tan-IIA and 5-FU on the protein expression of p53, p21, VEGF, MMP-2 and -7, topoisomerase I, Erb-B2, P-gp, LC-3II, Bcl-2 and β-actin in Colo205 cell xenograft tumors

Protein preparation. Total proteins were extracted as previously described (17). Briefly, the xenograft tumors were broken into pieces and the resulting thick liquid was then suspended in modified PRO-PREP™ buffer (iNtRON Biotechnology Inc., Korea) for 40 min at 4°C. Lysates were immediately centrifuged at 13,000 × g for 20 min at 4°C, and the supernatant was collected, aliquated (20 μl/ tube) and stored at −80°C until assay. The extracted protein concentrations were measured using the Bradford method (18).

Western blot analysis

All protein samples were separated by 8–15% SDS-PAGE as previously described (17). The SDS-separated proteins were equilibrated in transfer buffer (25 mM Tris, pH 8.5, 0.2 M glycine and 20% methanol) and transferred onto a PVDF membrane (Millipore, Bedford, MA, USA). The membranes were incubated with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 for 1 h. These membranes were then washed and incubated with appropriate dilutions of specific antibodies at 4°C overnight [including p53 (1:2000, MAB 1355; R&D Systems), p21 (1:2000, MAB 1047; R&D Systems), VEGF (1:500, V4758; Sigma), MMP-2 (1:200, MAB 902; R&D Systems) and MMP-7 (1:500, MAB 9071; R&D Systems), topoisomerase I (1:1000, T8573; Sigma), Erb-B2 (1:500, MAB 1129; R&D Systems), P-gp (1:500, P7965; Sigma), microtubule-associated protein light chain 3 (LC3)-II (1:1500, L7543; Sigma), Bcl-2 (1:500; R&D Systems) and β-actin (1:15000, A5441, Sigma)]. Following incubation with anti-mouse peroxidase-conjugated antibody (1:15000) (Sigma-Aldrich) the immunoreactive bands were visualized with an enhanced chemiluminescence (ECL, Millipore) detection kit. The detection of β-actin was used as an internal control in all of the data for western blot analysis. Immunoreactive bands were scanned (GS-800; Bio-Rad Life Science Products, Hercules, CA, USA) and analyzed using a digital scanning densitometer (Quantity One, v4.4.0; Bio-Rad Life Science Products).

Statistical analysis

Values were presented as the means ± SD. The Student's t-test was used to analyze statistical significance. P<0.05 was considered to indicate statistically significant differences for all tests.

Results

Synergistic effects of Tan-IIA and 5-FU in the Colo205 cell xenograft tumor model

SCID mice bearing Colo205 human colon cancer cell xenografts were divided randomly into 3 groups and then treated with 5-FU plus Tan-IIA, 5-FU only, or the vehicle alone. The tumor volumes and SCID mouse body weights were measured every 3 days. The xenograft tumor volumes were measured. The tumor volumes were 1,733.20±1,113.68, 1,134±795.95 and 537.42±437.36 mm3 for the control, 5-FU, and 5-FU plus Tan-IIA groups, respectively. The tumor volume enlarged ratios were 11.82±0.64, 11.5±0.7 and 4.38±0.31 for the control, 5-FU, and 5-FU plus Tan-IIA groups, respectively. The results showed that Tan-IIA could potentiate the effect of 5-FU in a colon cancer nude mouse model (Fig. 2A and B).

Figure 2. SCID mice bearing Colo205 human colon cancer cell xenografts were divided randomly into 3 groups and then treated with 5-FU plus Tan-IIA (2F2T group); 5-FU only (COF group) or vehicle alone (CND group). The tumor volumes were measured every 3 days. The tumor volume in each animal was estimated according to the formula: tumor volume (mm3) = L × W2/2 (where L is the length and W is the width) with the final measurement taken 4 weeks after tumor cell inoculation. (A) The results showed that Tan-IIA could potentiate the growth inhibitory effect of 5-FU in a colon cancer nude mouse model. (B) Our results showed that co-treatment with Tan-IIA plus 5-FU in the Colo205 xenograft model caused a reduction in the xenograft tumor volumes when compared to treatment with 5-FU only.

Effects of Tan-IIA and 5-FU on the protein expressions of p53, p21, VEGF, MMP-2 and -7, topoisomerase I, Erb-B2, P-gp, LC-3II, Bcl-2 and β-actin in Colo205 cell xenograft tumors

SCID mice bearing Colo205 human colon cancer cell xenograft tumors were divided randomly into 3 groups and then treated with 5-FU plus Tan-IIA, 5-FU only, or the vehicle alone. At the end of the 4-week dosing schedule, the SCID mice were sacrificed by CO2 inhalation and xenograft tumors dissected with total protein extracted for western blot analysis. The results showed that SCID mice with Colo205 cell xenograft tumors treated with 5-FU [20 mg/kg intraperitoneally (i.p.), every week on day 1] plus Tan-IIA (20 mg/kg i.p., every week on days 3 and day 5) had downregulated P-gp (Fig. 3A), LC-3II (Fig. 3B), VEGF (Fig. 3C), NF-κB p65 (Fig. 3D) and MMP-7 (Fig. 3E) expression when compared to the group treated only with 5-FU.

Figure 3. Our results showed that co-treatment with Tan-IIA plus 5-FU in the Colo205 xenograft model decreased the protein expressions of (A) P-gp, (B) LC3-II, (C) VEGF, (D) NF-κB p65 and (E) MMP-7 when compared to 5-FU only. Values are expressed as the means ± SD. *Significant difference at p<0.05, 5-FU plus Tan-IIA vs. the respective group without Tan-IIA treatment.

Discussion

P-gp is a cell membrane-associated protein, with high expression in cancer tissue, which functions as a drug export pump that decreases intracellular concentrations of chemotherapeutic agent (19,20). Our results showed that 5-FU plus Tan-IIA decreased the protein expression of P-gp when compared to the 5-FU group. It was documented that simultaneous and continuous exposure of colon cancer cells to low concentrations of 5-FU for 144 h showed a strong antagonism in vitro and that 14-days of continuous infusion of 5-FU significantly stimulated angiogenesis in vivo (21,22) Our results also showed that 5-FU increased the protein expression of VEGF when compared to the control group. The 5-FU plus Tan-IIA group decreased the protein expression of VEGF when compared to the 5-FU group. It has been well documented that LC3-II can be used as a marker of autophagy and can be detected using western blot analysis (23,24). Our results showed that the combination treatment of Tan-IIA plus 5-FU decreased the protein expression of LC3-II when compared to the 5-FU group. The combination treatment of autophagy inhibitor plus 5-FU significantly increased apoptotic cell death. 5-FU-induced apoptosis in colon cancer cells can be enhanced by the inhibition of autophagy (21). Elevated MMP-7 protein expression was a predictor of colon cancer recurrence and liver metastasis. High expression of MMP-7 was related to decreased survival (25). It has been well documented that the combination of gambogic acid and celastrol has a synergistic antitumor effect. The effect can be attributed to apoptosis induced by a decrease in NF-κB pathway activation, therefore, NF-κB p65 protein may be involved (26,27). The inhibition of NF-κB augments sensitivity to 5-FU/folinic acid in colon cancer (28). Our results showed that Tan-IIA plus 5-FU decreased the protein expression of MMP-7 and NF-κB p65 when compared to the 5-FU group. Tan-IIA plus 5-FU has a synergistic effect on Colo205 cell xenograft tumors. The effect can be primarily attributed to a decrease in MMP-7 and NF-κB p65 expression. These observations suggest that Tan-IIA potentiates the efficacy of 5-FU in a colon cancer nude SCID mouse model through downregulating P-gp, LC3-II, VEGF, MMP-7 and NF-κB p65 protein expression. This is the first report of 5-FU plus Tan-IIA downregulating P-gp, LC3-II, VEGF, MMP-7 and NF-κB p65 protein expression in vivo. The use of Tan-IIA may be a promising strategy for the adjuvant chemotherapy of colon cancer.

Acknowledgements

This study was supported by a grant (CCMP97-RD-041) from the Committee on Chinese Medicine and Pharmacy, Department of Health, Executive Yuan, Taiwan, R.O.C.

References